CN103215356A - Assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles - Google Patents
Assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles Download PDFInfo
- Publication number
- CN103215356A CN103215356A CN2013101167252A CN201310116725A CN103215356A CN 103215356 A CN103215356 A CN 103215356A CN 2013101167252 A CN2013101167252 A CN 2013101167252A CN 201310116725 A CN201310116725 A CN 201310116725A CN 103215356 A CN103215356 A CN 103215356A
- Authority
- CN
- China
- Prior art keywords
- primer
- hla
- seq
- hcp5
- test kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles. The assay kit comprises a polymerase chain reaction (PCR) reaction liquid containing primers for detecting HLA-B*57:01 and HCP5, wherein the primers for detecting HLA-B*57:01 are primers B57F, B57R1 and B57R2; the primer B57F has a sequence shown in SEQIDNO:1, the primer B57R1 has a sequence shown in SEQIDNO:2, and the primer B57R2 has a sequence shown in SEQIDNO:3; and the primers for detecting the HCP5 are primers 631R and 568GF, wherein the primer 631R has a sequence shown in SEQIDNO:4, and the primer 568GF has a sequence shown in SEQIDNO:5. The assay kit has high detection sensitivity and good specificity, and can be used for accurately separating genotypes without sequencing.
Description
Technical field
The invention belongs to biological technical field, relate to a kind of gene parting detecting reagent, particularly a kind of detection people HLA-B*57:01 and the allelic test kit of HCP5.
Background technology
Human leucocyte antigen (HLA) (HLA) is a cell surface molecule, is the oligogene system of regulation and control human body specific immune response, and the HLA gene is positioned at the short arm of a chromosome No. 6, is made of the allelotrope of numerous complicated, be at present known to the most complicated genetic system of polymorphism.By the HLA albumen of the genes encoding of HLA polymorphism to the susceptibility of the disease of immune-mediated or control, individual variation, and drug-induced side reaction in play an important role.Often detected in the past and carried out the HLA somatotype by serology, but result and out of true.Then be the genotype of analyzing HLA by the sequence of HLA generally now.Although the method for order-checking can obtain sequence information the most accurately, this can spend a large amount of time, and is also inapplicable in clinical.
Studies show that in recent years, the untoward reaction of the polymorphic and medicine of the gene of HLA-B is closely related.Some researchists find that when HIV carriers were treated, some patients resist AIDS medicine Abacavir (Abacavir is called for short ABC) can produce serious systemic anaphylaxis reaction, even threat to life.Further discover, there is substantial connection in the serious systemic anaphylaxis that HLA-B*57:01 and ABC produce, be one of best genetic marker of the present dependency of finding with drug reaction, the researchist Simon Mallal of this resistance project discloses in the patent WO03/068958A1 of 2003 applications and has made ABC produce the locus position and the detection method of drug reaction.Therefore, the treating AIDS guide requires the patient before using abc drug for this reason, and necessary examination HLA-B*57:01 gene is negative when detected result, can not use abc drug when promptly the patient does not contain the HLA-B*57:01 gene.HCP5 is and the unbalanced site rs2395029 of HLA-B*57:01 gene close linkage, show as single nucleotide polymorphism (SNP) 568G Nucleotide, detect HCP5 site single nucleotide polymorphism and can be used as a kind of surrogate markers of identifying the HLA-B*57:01 gene, the joint-detection of HLA-B*57:01 and HCP5 can significantly increase the reliability of HLA-B*57:01 gene identification.
Though there is dependency in the anaphylaxis that studies confirm that HLA-B*57:01 gene and anti-AIDS medicine Abacavir in the past, the treating AIDS guide also requires patient's necessary examination HLA-B*57:01 gene before using abc drug, but lacks the test kit to the HLA-B*57:01 gene test at present.Simultaneously, though present sequence measurement can obtain accurate sequence information, large-scale promotion when not being adapted at detecting.Therefore, obtain required high cost of HLA detected result and the major obstacle that just becomes effective enforcement treatment guide relative long detection time.There is huge demand for detecting with the HLA-B*57:01 simply, accurately and fast that low expense is carried out.Use the PCR sequence specific primers (sequence specific primer, SSP) analytical technology detects, this method is to use can the specific allelic primer of specific recognition, to detect sequence polymorphism behind the pcr amplification.According to certain allelic base character of decision, the sequence specific primers that design 3 ' first base of end is complementary with each allelic specificity base respectively, in the PCR reaction process, could realize duplicating fully of dna fragmentation when having only the specific allelic base complementrity of primer 3 ' first base of end and decision, carry out allelic somatotype according to having or not of PCR product.This method can make the stdn of the detection means that we carry out at present, need not order-checking, just can differentiate specific HLA gene by the sequence band.
But, easy, cheap though PCR-SSP only needs PCR just can determine genotypic SNP, be suitable for the requirement of molecule marker.But this technology is not used to detect genotypic SNP in a large number, and its major cause is the less stable of primer.
Domestic still do not have the HLA-B*57:01 gene detecting kit now, though pair test kit of HLA-B*57:01 gene test is arranged in the world, but adopt the method for universal primer amplification back order-checking to carry out the detection of HLA-B*57:01 gene, caused the sample detection time longer, it is higher to detect cost.
Summary of the invention
Technical problem to be solved by this invention provides a kind of detection people HLA-B*57:01 and the allelic test kit of HCP5, described this detection people HLA-B*57:01 and the allelic test kit of HCP5 have solved test kit of the prior art to detect time of HLA-B*57:01 gene long, the high technical problem of detection cost.
The invention provides a kind of detection people HLA-B*57:01 and the allelic test kit of HCP5, comprise and contain the PCR reaction solution that detects HLA-B*57:01 and HCP5 primer, the primer of described detection HLA-B*57:01 is primer B57F, primer B57R1, primer B57R2, the sequence of described primer B57F is shown in SEQ ID NO:1, the sequence of described primer B57R1 is shown in SEQ ID NO:2, the sequence of described primer B57R2 is shown in SEQ ID NO:3, the primer of described detection HCP5 is primer 631R and primer 568GF, the sequence of described primer 631R is shown in SEQ ID NO:4, the sequence of described primer 568GF shown in SEQ ID NO:5, described primer B57F, primer B57R1, primer B57R2, primer 631R and the concentration of primer 568GF in the PCR reaction solution are respectively 0.5 μ M.
Further, in described PCR reaction solution, also contain the internal reference primer, described internal reference primer is primer HGHF and primer HGHR24, the sequence of described primer HGHF shown in SEQ ID NO:6, the sequence of described primer HGHR24 shown in SEQ ID NO:7, described internal reference primer HGHF and the concentration of HGHR24 in the PCR reaction solution are respectively 0.2 μ M.
Further, in described PCR reaction solution, also comprise dyestuff, dNTPs and PCR buffer system.
Preferably, described dyestuff is an o-cresolsulfonphthalein, and concentration is 0.01% (wt/vol); The concentration of dNTPs is 0.2mM.
Preferably, described PCR buffer system is to be made up of Tris-HCl, Repone K, magnesium chloride and gelatin, in described buffer system, the concentration of described Tris-HCl is 10mM, the concentration of described Repone K is 50mM, the concentration of described magnesium chloride is 1.5mM, and the concentration of described gelatin is 0.001% (wt/vol).
Further, also comprise the Taq enzyme in the test kit of the present invention, the final usage quantity of described Taq enzyme is 0.3 unit/microlitre.
The present invention also provides the detection people HLA-B*57:01 that is used for above-mentioned test kit allelic primer, and its sequence is shown in SEQ ID NO:1.
The present invention also provides the detection people HLA-B*57:01 that is used for above-mentioned test kit allelic primer, and its sequence is shown in SEQ ID NO:2.
The present invention also provides the detection people HLA-B*57:01 that is used for above-mentioned test kit allelic primer, and its sequence is shown in SEQ ID NO:3.
The present invention also provides the detection people HCP5 that is used for above-mentioned test kit allelic primer, and its sequence is shown in SEQ ID NO:4.
The present invention also provides the detection people HCP5 that is used for above-mentioned test kit allelic primer, and its sequence is shown in SEQ ID NO:5.
Concrete, primer B57F(SEQ ID NO:1), B57R1(SEQ ID NO:2), B57R2(SEQ ID NO:3) is used to detect HLA-B*57:01 allelotrope, article two, reverse primer B57R1(SEQ ID NO:2) and B57R2(SEQ ID NO:3) can contain the SNP site of target fully, stopped possibility, and introduced base mismatch to increase the specificity of primer at 3 ' end of primer to this gene omission.Primer 631R(SEQ ID NO:4) and primer 568GF(SEQ ID NO:5) be used to detect the HCP5 gene, be positioned at karyomit(e) rs2395029SNP568G Nucleotide and HLA-B*57:01 allelotrope close linkage.Near design upstream and downstream primer this SNP site, wherein downstream primer 3 ' end is contained this SNP site, by detecting the rs2395029SNP site, can guarantee the accuracy of this test kit detected result.Primer HGHF(SEQ ID NO:6) and HGHR(SEQ ID NO:7) be the internal reference primer, amplifying human growth factor gene fragment, expanding fragment length 429bp correctly carries out to guarantee reaction system.
Primer sequence among the present invention is specific as follows:
1, detects HLA-B*57:01 allelotrope primer: PCR product 93bp
B57F（SEQ?ID?NO:1）：CCA?GGG?TCT?CAC?ATC?ATC?CAC?GTG
B57R1（SEQ?ID?NO:2）：GTA?ATC?CTT?GCC?GTC?GTA?GCC?GG
B57R2（SEQ?ID?NO:3）：GTA?ATC?CTT?GCC?GTC?GTA?CGC?AG
2, HCP5SNP (rs2395029) 568G primer: PCR product 153bp
631R（SEQ?ID?NO:4）：CAC?CTG?TCG?TGG?GAT?TAT?GCA?CTT?C
568GF（SEQ?ID?NO:5）：GGA?CAC?ATA?CTG?TCC?AAT?TCC?CGT?GG
3, internal reference primer: PCR product 272bp
HGHF（SEQ?ID?NO:6）：GCC?TTC?CCA?ACC?ATT?CCC?TTA?TCC?AGG
HGHR24（SEQ?ID?NO:7）：CTG?GAG?ACC?AGC?TCC?CAT?TGT?TAC?T
The present invention also provides the using method of above-mentioned detection kit, may further comprise the steps:
1) with sample DNA as template, adopt primer and reagent in the test kit to carry out PCR, described PCR finishes in PCR pipe or 96 orifice plates, in the reaction micropore, add templet gene group DNA, contain the PCR premix and the Taq polysaccharase of primer, after application of sample is finished with the reaction mixture mixing, centrifugal, carry out the PCR reaction, after PCR finishes, the PCR product is added to electrophoresis in the gel pore;
2), get final product there is which kind of gene in the judgement sample on this locus according to the visual result of gel electrophoresis.
Further, the reaction conditions of above-mentioned PCR is: 95 ° of C5min; Carry out 30 circulations according to following program successively again, 95 ° of C30s, 60 ° of C30s, 72 ° of C90s; Last 72 ° of C5min are cooled to 4 ° of C and can carry out detected through gel electrophoresis.
Further, the amount of described sample DNA as template is 20-50ng.
In above-mentioned steps 1) in, comprise the dyestuff o-cresolsulfonphthalein in the described PCR reaction solution, after PCR finishes, need not to add again sample-loading buffer (loading buffer), can directly the PCR product be added to electrophoresis in the gel pore.In above-mentioned steps 2) in, according to the quantity of band, to the detected result of gene have 2 kinds may: the HLA-B*57:01 gene is arranged, no HLA-B*57:01 gene.
Among the present invention, described sample DNA as template can be prepared according to existing extracting method by those skilled in the art.
The HLA-B*57:01 that the present invention is based on the PCR-SSP technological development compares existing other detection method with the HCP5 detection kit, have quick, easy, accurately, characteristics intuitively, experimental cost is low, and it is required only to need micro-sample can finish experiment.Detection kit of the present invention can be judged the allelotrope genotype, thereby finish the gene screening of HLA-B*57:01 very intuitively according to the band quantity of amplification rear electrophoresis.Because test kit detects the site with the closely linked HCP5rs2395029SNP of HLA-B*57:01 allelotrope simultaneously, greatly the increase of degree the reliability that detects, prevented to occur in the testing process false negative or false-positive may.The present invention is primer, dNTP, and PCR buffer system and dyestuff o-cresolsulfonphthalein are pre-mixed, and can save experimenter's operating time and workload greatly.Allelic two kinds of primers are mixed amplification simultaneously, realize that a hole finishes an allelic somatotype, satisfy high-throughout experiment demand, directly draw somatotype and examination result, have sensitivity, stable, characteristics accurately and efficiently.Under the situation that has suitable DNA sample, test kit of the present invention can be finished the experiment of whole gene screening and somatotype in 3 hours, had solved the problem that needs the HLA-B*57:01 gene screening when AIDS patient used the ABC treatment.
The stdn test kit of HLA-B*57:01 of the present invention and HCP5 gene SNP, adopting the Auele Specific Primer of optimizing to carry out PCR-SSP detects, can improve the stability of Auele Specific Primer, and use from the genomic dna of person under inspection's Stomatocyte or peripheral blood preparation and be sample, by single nucleotide polymorphism analysis, can accurately identify the HLA-B*57:01 gene.Simultaneously, because HLA-B*57:01 and HCP5rs2395029 show strong linkage disequilibrium, this test kit detects to HLA-B*57:01 and rs2395029SNP the time, can improve the accuracy of detection.Make it to be used for AIDS patient's examination, serve clinical treatment better,, reduce the generation of medicine source property untoward reaction for patient and the clinician who participates in the HIV-1 treatment provides the medication guide foundation.This will fill up the blank that domestic HLA-B*57:01 does not have the correlation detection test kit.Carrying out HLA-B*57:01 than the use PCR-SSP method of foreign study person report in 2004 detects, this test kit adopts new primer, and detect 2 SNP sites and internal reference gene simultaneously, and increased substantially the accuracy of detected result, be adapted at the large-scale promotion in the clinical detection.
Description of drawings
Fig. 1 is a HLA-B*57:01 genetic typing electrophoretogram.
Embodiment
Further set forth the present invention below in conjunction with embodiment.Embodiments of the invention only are used to illustrate the present invention, but not limit the scope of the invention.
Embodiment 1:
The PCR primer design of test kit of the present invention in the present embodiment, needed all the HLA allelotrope sequence datas of PCR design of primers are taken from international HLA database (IMGT/HLA), this database network address: http://www.ebi.ac.uk/ipd/imgt/hla/.Use the software Sequence Alignment Tool of this database to do the sequence contrast.Design of primers adopts manual method, and the primer of design carries out BLAST and detects in the GenBank of America NI H database, confirms that this primer energy specificity is in conjunction with HLA-B*57:01 allelotrope.In this test kit, key is to need this primer under specific PCR buffer system environment, special amplification HLA-B*57:01 gene, and promptly this primer has " sequence-specific SSP ".Pass through two solution routes in this design of primers, the one, the primer of actual tests different lengths makes it specificity in conjunction with target gene; The 2nd, introduce mutating alkali yl at primer 3 ' end, to improve primer bonded specificity.
In order to adopt specific PCR-SSP that HLA-B*57:01 and HCP5rs2395029SNP gene are carried out examination, at the specific upstream primer B57F(SEQ of upstream design in HLA-B*57:01 gene SNP s site ID NO:1); Comprising two primer B57R1(SEQ ID NO:2 of site design of HLA-B*57:01 gene SNP s) and B57R2(SEQ ID NO:3), make it contain the SNP site of target fully, and make the SNPs site be positioned at 3 ' end of downstream primer, in order to increase the specificity of primer, introduced base mismatch at 3 ' end of downstream primer.At the strong close linkage phenomenon of HLA-B*57:01 in the Human genome and HCP5rs2395029SNP568G Nucleotide, at rs2395029SNP568G Nucleotide upstream design Auele Specific Primer 631R(SEQ ID NO:4); Comprising the Position Design downstream primer 568GF(SEQ ID NO:5 in this SNP site), make this SNP site be positioned at 3 ' end of primer, and increase the specificity of primer by introduced base mismatch at 3 ' end.Simultaneously, according to design upstream and downstream primer HGHF(SEQ ID NO:6 the human growth factor) and HGHR(SEQ ID NO:7), as the internal reference primer.
1, detects HLA-B*57:01 allelotrope primer: PCR product 93bp
B57F（SEQ?ID?NO:1）：CCA?GGG?TCT?CAC?ATC?ATC?CAC?GTG
B57R1（SEQ?ID?NO:2）：GTA?ATC?CTT?GCC?GTC?GTA?GCC?GG
B57R2（SEQ?ID?NO:3）：GTA?ATC?CTT?GCC?GTC?GTA?CGC?AG
2, HCP5SNP (rs2395029) 568G primer: PCR product 153bp
631R（SEQ?ID?NO:4）：CAC?CTG?TCG?TGG?GAT?TAT?GCA?CTT?C
568GF（SEQ?ID?NO:5）：GGA?CAC?ATA?CTG?TCC?AAT?TCC?CGT?GG
3, internal reference primer: PCR product 272bp
HGHF（SEQ?ID?NO:6）：GCC?TTC?CCA?ACC?ATT?CCC?TTA?TCC?AGG
HGHR24（SEQ?ID?NO:7）：CTG?GAG?ACC?AGC?TCC?CAT?TGT?TAC?T
Embodiment 2: the preparation of test kit of the present invention
1, primer is synthetic: primer is synthetic by Shanghai Ying Jun Bioisystech Co., Ltd, and the sequence of primer is respectively SEQ ID NO:1-7, and concrete sequence as described in example 1 above.
2, the preparation of PCR reaction mixture: with primer 1-7, dNTPs, the dyestuff o-cresolsulfonphthalein, Taq enzyme buffer liquid mixes.The concentration that detects primer (SEQ ID NO:1-5) is 0.5 μ M, and the concentration of confidential reference items primer (SEQ ID NO:6-7) is 0.2 μ M; The concentration of dNTP is 0.2mM; The concentration of o-cresolsulfonphthalein is 0.01% (wt/vol); The PCR buffer system is: Tris-HCl10mM, Repone K 50mM, magnesium chloride 1.5mM, gelatin 0.001% (wt/vol).
To pack after above-mentioned PCR reaction mixture and the packing of Taq enzyme, form test kit.
Embodiment 3: the detection of HLA-B*57:01 and HCP5rs2395029SNP in the sample
Get the PCR pipe, in every pipe, add 8 μ l PCR reaction mixtures, add 1 μ l extractive genomic dna 50ng from 6 parts of HLA standard cell lines strain (all HLA standard cell lines strains are all bought from " IHWG Cell and DNA Bank ") respectively then, add the 0.30-0.5uTaq enzyme again., briefly centrifugal after application of sample is finished with the reaction mixture mixing, carry out the PCR reaction.
The reaction conditions of PCR is: 95 ° of C5min; Carry out 30 circulations according to following program successively again, 95 ° of C30s, 60 ° of C30s, 72 ° of C90s; Last 72 ° of C5min are cooled to 4 ° of C and can carry out detected through gel electrophoresis.
Use 0.5 * tbe buffer liquid, prepare 3% sepharose.Get the direct point sample of 5 μ l PCR products in gel pore.Use 0.5 * tbe buffer liquid, with 10V/ centimetre of electrophoresis 15-20 minute, Taking Pictures recording (see figure 1) under UV-light then.
The result judges: to the detected result of gene have 2 kinds may: the HLA-B*57:01 gene is arranged, no HLA-B*57:01 gene, according to analysis to electrophoretic band, detected result and sample protogene type conform to fully (table 1).
Table 1 uses the detected result and the true genotypic comparison of sample of test kit of the present invention
Embodiment 4: the evaluation specific detection of test kit of the present invention
Detect 163 examples by the standard DNA sample that international organization's consistency discussion cell and dna library (The IHWG Cell and DNA Bank) provide, wherein have 20 routine samples to contain the B*57:01 gene.Use test kit of the present invention to detect, detection method and as a result determination methods with embodiment 3.
After the detected result analysis, all these test kits of sample all can accurately detect.Have 20 routine samples of B*57:01 gene in 163 routine samples, all carry the HPC5rs2395029568G base, false positive and false negative result are 0(table 2).The presentation of results that great amount of samples detects, the specificity of this test kit is good, and detected result is accurate, meets the demand of clinical identification fully.
B*57:01 and HPC5 in the table 2 test kit of the present invention institute test sample
Claims (11)
1. one kind is detected people HLA-B*57:01 and the allelic test kit of HCP5, it is characterized in that: comprise and contain the PCR reaction solution that detects HLA-B*57:01 and HCP5 primer, the primer of described detection HLA-B*57:01 is primer B57F, primer B57R1, primer B57R2, the sequence of described primer B57F is as SEQ ID NO: shown in 1, the sequence of described primer B57R1 is as SEQ ID NO: shown in 2, the sequence of described primer B57R2 is as SEQ ID NO: shown in 3, the primer of described detection HCP5 is primer 631R and primer 568GF, the sequence of described primer 631R is as SEQ ID NO: shown in 4, the sequence of described primer 568GF is as SEQ ID NO: shown in 5, and described primer B57F, primer B57R1, primer B57R2, primer 631R and the concentration of primer 568GF in the PCR reaction solution are respectively 0.5 μ M.
2. a kind of detection people HLA-B*57:01 as claimed in claim 1 and the allelic test kit of HCP5, it is characterized in that: in described PCR reaction solution, also contain the internal reference primer, described internal reference primer is primer HGHF and primer HGHR24, the sequence of described primer HGHF is as SEQ ID NO: shown in 6, the sequence of described primer HGHR24 is as SEQ ID NO: shown in 7, described internal reference primer HGHF and the concentration of HGHR24 in the PCR reaction solution are respectively 0.2 μ M.
3. a kind of detection people HLA-B*57:01 as claimed in claim 1 and the allelic test kit of HCP5 is characterized in that: also comprise dyestuff in the PCR reaction solution of described test kit, dNTPs and PCR buffer system.
4. a kind of detection people HLA-B*57:01 as claimed in claim 3 and the allelic test kit of HCP5, it is characterized in that: the dyestuff in the described PCR reaction solution is an o-cresolsulfonphthalein, concentration is 0.01% (wt/vol).
5. a kind of detection people HLA-B*57:01 as claimed in claim 3 and the allelic test kit of HCP5, it is characterized in that: described PCR buffer system is for to be made up of Tris-HCl, Repone K, magnesium chloride and gelatin, in described buffer system, the concentration of described Tris-HCl is 10mM, the concentration of described Repone K is 50mM, the concentration of described magnesium chloride is 1.5mM, and the concentration of described gelatin is 0.001% (wt/vol).
6. a kind of detection people HLA-B*57:01 as claimed in claim 1 and the allelic test kit of HCP5 is characterized in that: also contain the Taq enzyme in the described test kit, the final usage quantity of described Taq enzyme is 0.3 unit/microlitre.
7. be used for the allelic primer of detection people HLA-B*57:01 of the described test kit of claim 1, it is characterized in that: its sequence is as SEQ ID NO: shown in 1.
8. be used for the allelic primer of detection people HLA-B*57:01 of the described test kit of claim 1, it is characterized in that: its sequence is as SEQ ID NO: shown in 2.
9. be used for the allelic primer of detection people HLA-B*57:01 of the described test kit of claim 1, it is characterized in that: its sequence is as SEQ ID NO: shown in 3.
10. be used for the allelic primer of detection people HCP5 of the described test kit of claim 1, it is characterized in that: its sequence is as SEQ ID NO: shown in 4.
11. be used for the allelic primer of detection people HCP5 of the described test kit of claim 1, it is characterized in that: its sequence is as SEQ ID NO: shown in 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101167252A CN103215356A (en) | 2013-04-07 | 2013-04-07 | Assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101167252A CN103215356A (en) | 2013-04-07 | 2013-04-07 | Assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103215356A true CN103215356A (en) | 2013-07-24 |
Family
ID=48813504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101167252A Pending CN103215356A (en) | 2013-04-07 | 2013-04-07 | Assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103215356A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103805701A (en) * | 2014-01-27 | 2014-05-21 | 希斯奇生物医药（上海）有限公司 | Detection method and kit of HLA (Human Leukocyte Antigen)-B*58:01 allele |
| CN104946779A (en) * | 2015-07-14 | 2015-09-30 | 陕西佰美基因股份有限公司 | TaqMan probe real-time fluorescent PCR method for detecting HLA-B*57:01 allele |
| CN105861673A (en) * | 2016-04-27 | 2016-08-17 | 上海荻硕贝肯生物科技有限公司 | Primers, kit and method for HLA (human leukocyte antigen) genotyping |
-
2013
- 2013-04-07 CN CN2013101167252A patent/CN103215356A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| A.M. MARTIN ET AL.: "HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing", 《TISSUE ANTIGENS》 * |
| SARA COLOMBO ET AL.: "The HCP5 Single-Nucleotide Polymorphism: A Simple Screening Tool for Prediction of Hypersensitivity Reaction to Abacavir", 《THE JOURNAL OF INFECTIOUS DISEASES》 * |
| SONIA RODRI´GUEZ-NO´VOA ET AL.: "Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701", 《J ANTIMICROB CHEMOTHER》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103805701A (en) * | 2014-01-27 | 2014-05-21 | 希斯奇生物医药（上海）有限公司 | Detection method and kit of HLA (Human Leukocyte Antigen)-B*58:01 allele |
| CN104946779A (en) * | 2015-07-14 | 2015-09-30 | 陕西佰美基因股份有限公司 | TaqMan probe real-time fluorescent PCR method for detecting HLA-B*57:01 allele |
| CN104946779B (en) * | 2015-07-14 | 2018-06-12 | 陕西佰美基因股份有限公司 | A kind of detection HLA-B*57:The TaqMan probe real time fluorescent PCR method of 01 allele |
| CN105861673A (en) * | 2016-04-27 | 2016-08-17 | 上海荻硕贝肯生物科技有限公司 | Primers, kit and method for HLA (human leukocyte antigen) genotyping |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105525357A (en) | Sequencing library construction method, and kit and application thereof | |
| CN103074434A (en) | CYP2C19 gene polymorphyism detection kit and detection method thereof | |
| CN103074436B (en) | Multi-gene detection kit for guiding administration of 5-fluorouracil and detection method of multi-gene detection kit | |
| CN108866207B (en) | Establishment and application of novel HIV-1 drug resistance detection method | |
| CN102925562B (en) | Kit and method for detecting aminoglycoside drug-induced deafness-sensitive gene | |
| CN103966228A (en) | RH blood type DEL-type RHD93T>A allele and detection method thereof | |
| CN103215356A (en) | Assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles | |
| CN101864492A (en) | Nucleic acid detection kit for aided diagnosis of ankylosing spondylitis | |
| CN103184291A (en) | Kit for detecting HLA-B*57:01 allele | |
| CN103602736A (en) | Kit for rapidly detecting five beta-thalassemia mutations and application thereof | |
| CN101135665B (en) | Reagent kit detecting elevated plain pneumochysis susceptibility based on mitochondria DNA T6680C mononucleotide polymorphism | |
| CN103045717A (en) | Method for detecting rifampin drug resistance of mycobacterium tuberculosis by using pyrosequencing technology | |
| CN104017898A (en) | Primer, kit and method for quickly detecting HLA-B*5801 allele | |
| CN104372073A (en) | Reagent and detection method capable of specifically detecting Mur antigen gene | |
| CN103937806A (en) | Rh blood group DEL phenotype RHD838>A allele and detection method thereof | |
| CN102586433A (en) | Deafness predisposing gene 12S rRNA (ribosomal ribonucleic acid) 1494C>T fluorescence detection kit and application thereof | |
| CN103757109B (en) | Primer composition and multiple-gene detection kit for guiding administration of thiazine diuresis drugs and application method thereof | |
| CN105755129A (en) | STR typing method for loca D8S1179 based on next generation sequencing | |
| CN108531599A (en) | A kind of kit and method of people HLA-B*5801 genotype | |
| CN105586392A (en) | Method for evaluating maternal cell contamination degree in fetal sample | |
| CN116356054A (en) | Kit for detecting common pathogenic microorganisms and drug resistance genes and detection method | |
| WO2022221605A2 (en) | Detection of sars-cov-2 variant | |
| CN103757110B (en) | A kind of vibrio cholerae analyzes parting kit | |
| CN107937493A (en) | A kind of hair clip Mdification primer for allele PCR | |
| CN102660636A (en) | Deafness susceptibility gene 12S rRNA1555A G fluorescence detection kit and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130724 |